47 results
10-K
2023 FY
EX-4.11
GALT
Galectin Therapeutics Inc
Annual report
29 Mar 24
7:51am
10-K
2023 FY
EX-4.12
GALT
Galectin Therapeutics Inc
Annual report
29 Mar 24
7:51am
SC 13D/A
EX-4
10X Fund, L.P.
1 Dec 23
GALECTIN THERAPEUTICS / 10X Fund ownership change
4:38pm
8-K
EX-4.1
GALT
Galectin Therapeutics Inc
26 Jul 22
Galectin Therapeutics Announces $60 Million Credit Line
7:57am
10-K
2020 FY
EX-4.20
GALT
Galectin Therapeutics Inc
Annual report
31 Mar 21
7:51am
8-K
EX-4.1
ypw8dm4noatnmqit73ce
15 Jan 19
Board Chairman Richard Uihlein extends existing $10 million unsecured line of credit for two additional years
7:55am
8-K
EX-4.3
bwukkq89ij3
15 Jan 19
Board Chairman Richard Uihlein extends existing $10 million unsecured line of credit for two additional years
7:55am
8-K
EX-4.2
rstj9itgffcodc
15 Jan 19
Board Chairman Richard Uihlein extends existing $10 million unsecured line of credit for two additional years
7:55am
8-K/A
EX-4.1
5ychaml9
3 Jan 19
Entry into a Material Definitive Agreement
8:30am
8-K
EX-4.1
l4jpn8p ar
19 Dec 17
Galectin Therapeutics Announces $10 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Into 2019
12:00am
8-K
EX-4.1
o8f rashnh89xwfskyzb
29 Dec 16
Galectin Therapeutics Announces $4 Million In New Equity Financings
12:00am
8-K
EX-4.1
8ljgkxm73o46yja
27 Sep 16
Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced Fibrosis
12:00am
8-K
EX-4.2
zlye01uyn
27 Sep 16
Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced Fibrosis
12:00am
8-K
EX-4.1
uhd79f7o xxf6l1ev9pn
20 Nov 15
Galectin Therapeutics Announces Pricing of $9.8 Million
12:00am